Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

被引：7

作者：

Diefenbach, Catherine S. ^{[1
]}

Jegede, Opeyemi ^{[2
]}

Ansell, Stephen M. ^{[3
]}

Steidl, Christian ^{[4
]}

Natkunam, Yasodha ^{[5
,6
]}

Scott, David W. ^{[7
]}

Mehta-Shah, Neha ^{[8
]}

Amengual, Jennifer E. ^{[9
]}

Forlenza, Christopher J. ^{[10
]}

Cole, Peter D. ^{[11
]}

Bartlett, Nancy L. ^{[12
]}

David, Kevin A. ^{[13
]}

Advani, Ranjana H. ^{[14
]}

Ambinder, Richard F. ^{[15
]}

Thomas, Sachdev ^{[16
]}

Ibrahimi, Sami ^{[17
]}

Kahl, Brad S. ^{[18
]}

机构：

[1] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[2] CIMAC CIDC Network, Dept Data Sci, Boston, MA USA

[3] Mayo Clin, Div Hematol, Rochester, MN USA

[4] BC Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada

[5] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA USA

[6] Stanford Univ, Med Ctr, Stanford, CA USA

[7] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada

[8] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA

[9] Columbia Univ, Div Hematol & Oncol, Lymphoma Program, Irving Med Ctr, New York, NY USA

[10] Mem Sloan Kettering Canc Ctr, West Harrison, NY USA

[11] NJ Rbt Wood Johnson Univ Hosp, Rutgers Ca Inst, New Brunswick, NJ USA

[12] Washington Univ, Siteman, Sch Med, St Louis, MO USA

[13] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[14] Stanford Univ, Div Hematol & Oncol, Dept Med, Stanford, CA USA

[15] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[16] VA Cent Calif Hlth CARE Syst, Fresno, CA USA

[17] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[18] Washington Univ, Sch Med St Louis, St Louis, MO USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-184531

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] A Phase I Study With an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 18 - 19
[2] A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)
Diefenbach, Catherine
Hong, Fangxin
Ambinder, Richard F.
Cohen, Jonathon B.
Robertson, Michael
David, Kevin A.
Advani, Ranjana H.
Fenske, Timothy S.
Barta, Stefan Klaus
Palmisano, Neil
Svoboda, Jakub
Morgan, David
Karmali, Reem
Kahl, Brad S.
Ansell, Stephen M.
BLOOD, 2018, 132
[3] A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412).
Diefenbach, Catherine S. Magid
Li, Hailun
Kahl, Brad S.
Robertson, Michael J.
Cohen, Jonathan
Advani, Ranjana H.
Ambinder, Richard
Fenske, Timothy S.
Ansell, Stephen Maxted
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] A PHASE I STUDY WITH AN EXPANSION COHORT OF THE COMBINATION OF IPILIMUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412)
Diefenbach, C. S. M.
Hong, F.
Ambinder, R. F.
Cohen, J. B.
Robertson, M. J.
Fenske, T. S.
Advani, R.
Kahl, B. S.
Ansell, S.
HAEMATOLOGICA, 2016, 101 : 44 - 45
[5] Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)
Diefenbach, Catherine S.
Hong, Fangxin
Cohen, Jonathon B.
Robertson, Michael J.
Ambinder, Richard F.
Fenske, Timothy S.
Advani, Ranjana H.
Kahl, Brad S.
Ansell, Stephen
BLOOD, 2015, 126 (23)
[6] Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)
Diefenbach, Catherine S.
Hong, Fangxin
David, Kevin A.
Cohen, Jonathon
Robertson, Michael
Advani, Ranjana
Palmisiano, Neil D.
Ambinder, Richard F.
Kahl, Brad S.
Ansell, Stephen
BLOOD, 2016, 128 (22)
[7] Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)
Hong, Fangxin
Thanarajasingam, Gita
Ansell, Stephen M.
Ambinder, Richard F.
Cohen, Jonathon B.
Robertson, Michael
David, Kevin A.
Advani, Ranjana H.
Fenske, Timothy S.
Barta, Stefan Klaus
Palmisiano, Neil
Svoboda, Jakub
Morgan, David
Karmali, Reem
Witzig, Thomas E.
Dueck, Amylou C.
Novotny, Paul
Kahl, Brad S.
Diefenbach, Catherine
BLOOD, 2018, 132
[8] Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)
Diefenbach, Catherine S.
Gonzalez-Kozlova, Edgar
Del Valle, Diane Marie
Huang, Hsin-Hui
Jegede, Opeyemi
Barcessat, Vanessa
Tuballes, Kevin
Kelly, Geoffrey
Patel, Manishkumar
Xie, Hui
Harris, Jocelyn
Argueta, Kimberly
Nie, Kai
Moravec, Radim
Altreuter, Jennifer
Duose, Dzifa Yawa
Kahl, Brad S.
Ansell, Stephen M.
Yu, Joyce
Cerami, Ethan
Lindsay, James
Wistuba, Ignacio
Kim-Schulze, Seunghee
Gnjatic, Sacha
BLOOD, 2023, 142
[9] Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
Herrera, Alex F.
Moskowitz, Alison J.
Bartlett, Nancy L.
Vose, Julie M.
Ramchandren, Radhakrishnan
Feldman, Tatyana A.
LaCasce, Ann S.
Ansell, Stephen M.
Moskowitz, Craig H.
Fenton, Keenan
Ogden, Carol Anne
Taft, David
Zhang, Qu
Kato, Kazunobu
Campbell, Mary
Advani, Ranjana H.
BLOOD, 2017, 130
[10] Results From a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 13

← 1 2 3 4 5 →